Evidence for neuroprotection and remyelination using imaging techniques

Neurology

Volumn 68, Issue 22 SUPPL. 3, 2007, Pages

  Arnold, Douglas L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB;

BRAIN ATROPHY; BRAIN SIZE; CONFERENCE PAPER; DEMYELINATION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REMYELINIZATION; SPINAL CORD ATROPHY; WHITE MATTER;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; NERVE REGENERATION; NEUROPROTECTIVE AGENTS;

EID: 34249790279     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000275237.28259.9d     Document Type: Conference Paper

References (56)

1. Lassmann H. Recent neuropathological findings in MS - implications for diagnosis and therapy. J Neurol 2004;251(suppl 4):IV2-5.
2. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005;233:3-13.
3. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(pt 11):2705-2712.
4. Markovic-Plese S, McFarland HF. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 2001;1:257-262.
5. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241.
6. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36(suppl):S86-90.
7. Comi G, Filippi M, Wolinsky JS, for the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
8. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
9. Simon JH, Jacobs LD, Campion M, et al., for Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
10. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
11. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121(pt 1):103-113.
12. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis. I. Inflammation and lesions. Front Biosci 2004;9:665-683.
13. Matthews PM, Arnold DL. Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Curr Opin Neurol 2001;14:279-287.
14. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999;122:1933-1939.
15. De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565-1571.
16. Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 2002;249:1382-1390.
17. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119(pt 3):715-722.
18. Narayana PA, Wolinsky JS, Jackson EF, McCarthy M. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging 1992;2:263-270.
19. Tiberio M, Chard DT, Altmann DR, et al. Metabolite changes in early relapsing-remitting multiple sclerosis: a two year follow-up study. J Neurol 2006;253:224-230.
20. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
21. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b. J Neurol 2001;248:979-986.
22. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-1477.
23. De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997;49:1138-1141.
24. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632-636.
25. Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001;7:49-58.
26. Dousset V, Gayou A, Brochet B, Caille JM. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology 1998;51:1150-1155.
27. Chen JT, Collins DL, Freedman MS, Atkins HL, Arnold DL, and The Canadian MS/BMT Study Group. Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. Neuroimage 2005;25:1272-1278.
28. Pike GB, de Stefano N, Narayanan S, Francis GS, Antel JP, Arnold DL. Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR 1999;20:829-837.
29. Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 2000;215:824-830.
30. Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR 2000;21:1034-1038.
31. Santos AC, Narayanan S, de Stefano N, et al. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. J Neurol 2002;249:662-668.
32. Chen JT, Narayanan S, Collins DL, Freedman MS, Atkins HL, the Canadian MS BMT Study Group, and Arnold DL. All enhancing voxels are not equal: quantifying destruction and repair within gadolinium-enhancing lesions in multiple sclerosis. Proc Int Soc Magn Reson Med 2005;319. Abstract.
33. Minagar A, Toledo EG, Alexander JS, Kelley RE. Pathogenesis of brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004;14 (3 suppl):5s-10s.
34. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-1695.
35. Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14-year follow up study. J Neurol Neurosurg Psychiatry 2003;74:1551-1554.
36. Richert ND, Howard T, Frank JA, et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006;66:551-556.
37. Molyneux PD, Kappos L, Polman C, et al., and the European Study Group on Interferon Beta-1b in Secondary Progressive Multiple Sclerosis. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000;123(pt 11):2256-2263.
38. Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N. A Wallerian degeneration pattern in patients at risk for MS. Neurology 2000;54:1155-1160.
39. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:279-285.
40. De Stefano N, Iannucci G, Sormani MP, et al. MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 2002;249:1072-1077.
41. Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 2004;62:624-627.
42. Jacobs LD, Cookfair DL, Rudick RA, et al., for the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
43. Paty DW, Li DK, for the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
44. Polman CH, O'Connor PW, Havrdova E, et al., for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
45. Filippi M, Rovaris M, Rocca MA, et al., and the European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733.
46. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407-413.
47. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L, and the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999;53:1698-1704.
48. Hardmeier M, Wagenpfeil S, Freitag P, et al., for the European IFN β-1a in Relapsing MS Dose Comparison Trial Study Group. Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a. Neurology 2005;64:236-240.
49. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-1496.
50. Jones CK, Zhao GJ, Li DKB, Paty DW, Group tMMR, Group TPS. Atrophy in multiple sclerosis: results of analysis of the PRISMS trial. Neurology 2001;56(suppl 3):A379. Abstract.
51. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;54:813-817.
52. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62:1432-1434.
53. Narayanan S, Caramanos Z, Arnold DL. The effect of glatiramer acetate on axonal integrity in multiple sclerosis. Mult Scler 2004;10:S256. Abstract.
54. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:646-651.
55. Parry A, Corkill R, Blamire AM, et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003;250:171-178.
56. Richert N, Bagnato F, Howard T, et al. Whole brain magnetization transfer analysis of relapsing-remitting multiple sclerosis patients treated with IFNB-1b or glatiramer acetate. Presented at ECTRIMS, Milan, Italy, 2003.